Initial results of a phase i dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer

Kyle E. Rusthoven, Steven J. Feigenberg, David Raben, Madeleine Kane, John I. Song, Nicos Nicolaou, Ranee Mehra, Barbara Burtness, John Ridge, Robyn Swing, Miriam Lango, Roger Cohen, Antonio Jimeno, Changhu Chen